AdAlta Limited (1AD) is engaged in the discovery and development of next generation protein-based therapeutics. AdAlta's aim is to deliver antibody-like precision in applications beyond the limits of traditional antibody formats. The Company solves challenging drug targeting problems to generate a promising new class of single domain antibody-enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.